Murphy Pohlad Asset Management LLC Sells 20 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Murphy Pohlad Asset Management LLC lessened its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 1.3% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,580 shares of the biopharmaceutical company’s stock after selling 20 shares during the quarter. Murphy Pohlad Asset Management LLC’s holdings in Regeneron Pharmaceuticals were worth $830,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Activest Wealth Management boosted its stake in shares of Regeneron Pharmaceuticals by 110.5% during the first quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 21 shares during the period. Costello Asset Management INC purchased a new stake in shares of Regeneron Pharmaceuticals during the first quarter valued at approximately $27,000. Saudi Central Bank purchased a new stake in shares of Regeneron Pharmaceuticals during the first quarter valued at approximately $27,000. Migdal Insurance & Financial Holdings Ltd. purchased a new stake in shares of Regeneron Pharmaceuticals during the second quarter valued at approximately $31,000. Finally, Colonial Trust Advisors purchased a new stake in shares of Regeneron Pharmaceuticals during the first quarter valued at approximately $32,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

REGN opened at $654.04 on Friday. The stock has a fifty day simple moving average of $580.56 and a two-hundred day simple moving average of $564.66. The company has a current ratio of 4.06, a quick ratio of 3.72 and a debt-to-equity ratio of 0.09. The company has a market cap of $69.32 billion, a price-to-earnings ratio of 15.66, a price-to-earnings-growth ratio of 2.03 and a beta of 0.31. Regeneron Pharmaceuticals, Inc. has a 12-month low of $476.49 and a 12-month high of $883.15.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $9.73 by $2.10. The business had revenue of $3.75 billion during the quarter, compared to the consensus estimate of $3.57 billion. Regeneron Pharmaceuticals had a return on equity of 13.76% and a net margin of 32.13%.The firm’s quarterly revenue was up .9% compared to the same quarter last year. During the same quarter in the prior year, the company earned $12.46 earnings per share. Research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, December 5th. Shareholders of record on Thursday, November 20th will be issued a $0.88 dividend. The ex-dividend date is Thursday, November 20th. This represents a $3.52 dividend on an annualized basis and a yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio is 8.43%.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on REGN shares. Morgan Stanley dropped their price objective on Regeneron Pharmaceuticals from $761.00 to $756.00 and set an “overweight” rating for the company in a research note on Friday, October 10th. Citigroup upped their target price on Regeneron Pharmaceuticals from $660.00 to $700.00 and gave the company a “buy” rating in a report on Wednesday. UBS Group restated a “neutral” rating on shares of Regeneron Pharmaceuticals in a report on Friday, August 1st. Truist Financial decreased their target price on Regeneron Pharmaceuticals from $940.00 to $812.00 and set a “buy” rating for the company in a report on Monday, August 11th. Finally, Wells Fargo & Company upped their target price on Regeneron Pharmaceuticals from $580.00 to $615.00 and gave the company an “equal weight” rating in a report on Wednesday. Three analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating, seven have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $813.78.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.